|MDACC Study No:||2010-0268 (clinicaltrials.gov NCT No: NCT01149915)|
|Title:||A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, in Patients with Advanced Leukemias|
|Principal Investigator:||Marina Konopleva|
|Treatment Agent:||Oral Hypoxyprobe-1; TH-302|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of TH-302 that can be given to patients with leukemia. The safety of this drug
will also be studied.